drugset
drugset / Trial / NCT05394337

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

NCT05394337 ↗

Phase 1/2 Recruiting 10 enrolled M.D. Anderson Cancer Center
Non-randomizedSingle-groupSingle-blindTreatment

Summary

To learn if the combination of atezolizumab and tiragolumab can help to control bladder cancer when it is given before surgery to remove the bladder and tumor.

Timeline

Start
2023-02-23
Primary completion
2028-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody 1200 mg Intravenous
Subject Tiragolumab Monoclonal antibody 600 mg Intravenous

Indications

metastatic malignant neoplasm